AQP Pharmaceuticals

AQP Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule modulators of aquaporins, a family of water channel proteins. The company's primary research targets Aquaporin-4 (AQP4) and Aquaporin-1 (AQP1) to address critical unmet needs in neurology and ophthalmology. Their lead programs aim to treat conditions such as neuromyelitis optica (NMO), cerebral edema following stroke or traumatic brain injury, and various fluid-related disorders. By leveraging deep expertise in aquaporin structural biology and pharmacology, AQP Pharmaceuticals seeks to pioneer a new class of therapeutics for water homeostasis disorders.